text:
Research Topics
Genomes and Genes
viral oncogene proteins
Summary: Products of viral oncogenes, most commonly retroviral oncogenes. They usually have transforming and often protein kinase activities.
Top Publications
Research Grants
Scientific Experts
Detail Information
Publications265 found, 100 shown here
- Papillomaviruses and cancer: from basic studies to clinical applicationHarald zur Hausen
Deutsches Krebsforschungszentrum, Heidelberg, Germany
Nat Rev Cancer 2:342-50. 2002..Epidemiological studies have underlined that HPVs are the main aetiological factor for cervical cancer. But how has this knowledge been translated into the clinic to allow the prevention, screening and treatment of cervical cancer?..
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideJ M Walboomers
Department of Pathology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
J Pathol 189:12-9. 1999..The extreme rarity of HPV-negative cancers reinforces the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening...
- The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53M Scheffner
Laboratory of Tumor Virus Biology, National Cancer Institute, Bethesda, Maryland 20892
Cell 75:495-505. 1993..The ubiquitination of p53 requires the E1 enzyme and a novel E2 in mammalian cells, while E3 activity is conferred by the E6-E6-AP complex. Furthermore, E6-AP appears to have ubiquitin-protein ligase activity in the absence of E6...
- Efficient intracellular assembly of papillomaviral vectorsChristopher B Buck
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892 4263, USA
J Virol 78:751-7. 2004..The results suggest that the intracellular assembly of papillomavirus structural proteins around heterologous reporter plasmids is surprisingly promiscuous and may be driven primarily by a size discrimination mechanism...
- The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene productN Dyson
Cold Spring Harbor Laboratory, NY 11724
Science 243:934-7. 1989..These results suggest that these three DNA viruses may utilize similar mechanisms in transformation and implicate RB binding as a possible step in human papilloma virus-associated carcinogenesis...
- Human papillomavirus immortalization and transformation functionsKarl Munger
Department of Pathology, Harvard Medical School, Armenise Building 544, 200 Longwood Avenue, Boston, MA 02115 5701, USA
Virus Res 89:213-28. 2002..This paper will review the state of the field at the time of the 19th International Papillomavirus Workshop in September 2001 with respect to the HPV encoded oncoproteins...
- Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligaseS Nakagawa
Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, New Jersey 08855, USA
Mol Cell Biol 20:8244-53. 2000....
- Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor proteinT Kiyono
Laboratory of Viral Oncology, Aichi Cancer Center, Research Institute, 1 1 Kanokoden, Chikusa ku, Nagoya 464, Japan
Proc Natl Acad Sci U S A 94:11612-6. 1997..These results suggest an intriguing possibility that interaction between the E6 protein and hDLG or other PDZ domain-containing proteins could be an underlying mechanism in the development of HPV-associated cancers...
- Arrangement of L2 within the papillomavirus capsidChristopher B Buck
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 5624, USA
J Virol 82:5190-7. 2008..This structural information should facilitate investigation of L2 function during the assembly and entry phases of the papillomavirus life cycle...
- Pathogenesis of human papillomaviruses in differentiating epitheliaMichelle S Longworth
Department of Microbiology Immunology, The Fineberg Medical School, Northwestern University, 303 E Chicago Ave, Chicago, IL 60611, USA
Microbiol Mol Biol Rev 68:362-72. 2004..The characterization of the cellular targets of these viral proteins and the mechanisms regulating the differentiation-dependent viral life cycle remain active areas for the study of these important human pathogens...
- siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cellsKarin Butz
Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 242, Heidelberg D 69120, Germany
Oncogene 22:5938-45. 2003..Thus, by sequence-specific targeting of antiapoptotic genes, siRNAs may be developed into novel therapeutics that can efficiently correct the apoptosis deficiency of cancer cells...
- Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interferenceMing Jiang
YCR P53 Research Group, Department of Biology, University of York, York YO10 5DD, UK
Oncogene 21:6041-8. 2002....
- Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancerHugo Arias-Pulido
Department of Molecular Genetics and Microbiology, School of Medicine, Health Sciences Center, University of New Mexico, Albuquerque, NM 87111, USA
J Clin Microbiol 44:1755-62. 2006..HPV-16 E2 expressed from intact episomes may act in trans to regulate integrated genome expression of E6 and E7...
- The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activitiesAnny Shai
McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706, USA
Cancer Res 67:1626-35. 2007..E6 also prevented the expression of p16 in tumors of the reproductive tract through a mechanism mediated by the interaction of E6 with alpha-helix partners...
- Biological activities and molecular targets of the human papillomavirus E7 oncoproteinK Munger
Department of Pathology and Harvard Center for Cancer Biology, Harvard Medical School, Boston, MA 02115, USA
Oncogene 20:7888-98. 2001..The transforming activities of E7 largely reflect this important function...
- Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor proteinS S Lee
Division of Molecular Virology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Proc Natl Acad Sci U S A 94:6670-5. 1997....
- Association of human papillomavirus types 16 and 18 E6 proteins with p53B A Werness
Laboratory of Tumor Virus Biology, National Cancer Institute, Bethesda, MD 20892
Science 248:76-9. 1990....
- Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sitesS T Oh
Department of Microbiology-Immunology, Northwestern University Medical School, Chicago, Illinois 60611, USA
J Virol 75:5559-66. 2001..This indicates that it is the combinatorial binding of factors to Myc and Sp1 cis elements that is responsible for hTERT induction by E6...
- The l2 minor capsid protein of human papillomavirus type 16 interacts with a network of nuclear import receptorsMedha S Darshan
Biology Department, Boston College, Higgins Hall Room 578, 140 Commonwealth Avenue, Chestnut Hill, MA 02467, USA
J Virol 78:12179-88. 2004..Together the data suggest that HPV16 L2 interacts via its NLSs with a network of karyopherins and can enter the nucleus via several import pathways mediated by Kapalpha(2)beta(1) heterodimers, Kapbeta(2), and Kapbeta(3)...
- Human papillomavirus type 16 E1circumflexE4 contributes to multiple facets of the papillomavirus life cycleTomomi Nakahara
McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, 53706, USA
J Virol 79:13150-65. 2005..These data support the hypothesis that E1(circumflex)E4 is a multifunctional protein and that the different properties of E1(circumflex)E4 contribute to different processes in both the early and late stages of the virus life cycle...
- Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16G Veress
Department of Microbiology, University Medical School of Debrecen, Hungary
J Gen Virol 80:1035-43. 1999..The transcriptional transactivation potentials of the HPV-16 E2 isolates differed only slightly from each other, and the differences seemed to be independent of the taxonomic position of the isolates...
- Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1Thomas Iftner
Sektion Experimentelle Virologie, Universitatsklinikum Tuebingen, Elfriede Aulhorn Strasse 6, D 72076 Tuebingen, Germany
EMBO J 21:4741-8. 2002..These data identify a novel link between small DNA tumour viruses and DNA repair pathways, and suggest a novel explanation for the development of genomic instability in tissue cells persistently infected with papillomaviruses...
- Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteinsTae Woo Kim
Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
J Clin Invest 112:109-17. 2003..Thus, coadministration of DNA vaccines with DNA encoding antiapoptotic proteins represents an innovative approach to enhance DNA vaccine potency...
- Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7N R Chu
StressGen Biotechnologies Corporation, Victoria, B C, Canada, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
Clin Exp Immunol 121:216-25. 2000..These studies extend previous observations on the induction of cytotoxic T lymphocytes by hsp fusion proteins and are consistent with the clinical application of hspE7 as an immunotherapy for human cervical and anal dysplasia and cancer...
- Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytesM Nees
Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, Bethesda, Maryland, USA
J Virol 75:4283-96. 2001..Thus, high-level expression of the HPV-16 E6 protein in differentiating keratinocytes directly alters expression of genes that influence host resistance to infection and immune function...
- Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histologyS M A Kulmala
Department of Oral Pathology, Institute of Dentistry, University of Turku, Finland
J Clin Pathol 59:513-7. 2006....
- Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesisYves Nominé
Equipe Oncoprotéine, UMR CNRS 7100, Ecole Superieure de Biotechnologie de Strasbourg, Boulevard Sebastien Brant, BP 10413, 67412 Illkirch Cedex, France
Mol Cell 21:665-78. 2006..E6 structure-function analysis provides new clues for understanding and counteracting the complex pathways of HPV-mediated pathogenesis...
- The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivoMarie L Nguyen
McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706, USA
J Virol 77:6957-64. 2003..However, the K14E6(Delta 146-151) mice fail to display epithelial hyperplasia. These results indicate that an interaction of E6 with PDZ partners is necessary for its induction of epithelial hyperplasia...
- Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteinsS S Lee
Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030, USA
J Virol 74:9680-93. 2000....
- Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivoX Y Niu
Department of Obstetrics and Gynecology, Sichuan University Huaxi the Second Hospital, Chengdu, Sichuan Province, China
Int J Gynecol Cancer 16:743-51. 2006..RNA interference exists, and the interference to HPV 16 E6 is specific and highly efficient both in vitro and in vivo...
- alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLPC S Yoon
Genome Research Center, Korea Research Institute of Bioscience and Biotechnology, Taejeon, 305-600, Korea
Biochem Biophys Res Commun 283:668-73. 2001..The degree of binding of HPV-VLP matched the alpha(6) integrin expression level in cell lines but was not correlated with beta(1) and beta(4) levels, which suggests that alpha(6) integrin is the main receptor of HPV type 16...
- Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancersBassam Abdulkarim
Laboratoire UPRES EA N degrees 27 10 Radiosensibilité Radiocarcinogénèse humaine and Unité METSI, Institut Gustave Roussy, 94805 Villejuif, France
Oncogene 21:2334-46. 2002..This study provides the basis for a new anticancer strategy to enhance the antitumor effect of ionizing radiation in HPV-related cancers, without increase deleterious effects...
- Predicting indirect readout effects in protein-DNA interactionsYongli Zhang
Departments of Chemistry and Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511, USA
Proc Natl Acad Sci U S A 101:8337-41. 2004..The sole exception was traced to differential magnesium ion binding...
- Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteinsMako Narisawa-Saito
Virology Division, National Cancer Center Research Institute, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
Cancer Sci 98:1505-11. 2007..In the present article, the mechanisms of HPV16 E6- and E7-induced multistep carcinogenesis and recently identified functions of these onco-proteins are reviewed...
- Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptidesSander Zwaveling
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
J Immunol 169:350-8. 2002..Because the vaccine types used in this study are easy to prepare under good manufacturing practice conditions and are safe to administer to humans, these data provide important information for future clinical trials...
- The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instabilityStefan Duensing
Department of Pathology and Harvard Center for Cancer Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Res 62:7075-82. 2002..Our results therefore suggest that HPV oncoproteins are a source for both numerical and structural chromosome instability during HPV-associated carcinogenesis...
- Papillomavirus E6 and E7 proteins and their cellular targetsTrisha M Wise-Draper
Division of Hematology Oncology, Department of Pediatrics, Cincinnati Children s Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
Front Biosci 13:1003-17. 2008..We will summarize here current insights into E6 and E7 interactions with specific cellular targets that stimulate aspects of the viral life cycle, interfere with cell cycle controls and promote carcinogenic processes...
- TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16Uzma A Hasan
International Agency for Research on Cancer World Health Organization, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
J Immunol 178:3186-97. 2007....
- In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNAMitsuo Yoshinouchi
Department of Obstetrics and Gynecology, Okayama University Medical School, 700 8558, Okayama, Japan
Mol Ther 8:762-8. 2003..Our results show HPV E6 siRNA as a candidate for gene-specific therapy for HPV-related cervical cancer...
- Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteinsEmma J Davidson
Immunology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, United Kingdom
Cancer Res 63:6032-41. 2003..Local immune infiltration may be a critical factor in potential responsiveness to vaccine therapy in HPV-associated neoplasia and should be carefully monitored in future placebo-controlled trials of immunotherapy for VIN...
- Mechanisms of cell transformation by papillomavirus E5 proteinsD DiMaio
Department of Genetics, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
Oncogene 20:7866-73. 2001..Further analysis of these unique mechanisms of viral transformation will yield new insight into the regulation of growth factor receptor activity and cellular signal transduction pathways...
- Epidemiological and functional implications of molecular variants of human papillomavirusL Sichero
Instituto Ludwig de Pesquisa sobre o Câncer, Sao Paulo, SP, Brasil
Braz J Med Biol Res 39:707-17. 2006..These results are also important for the development of vaccines and to determine the extent to which immunization with L1 virus-like particles of one variant could induce antibodies that cross-neutralize other variants...
- Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesisH zur Hausen
Deutsches Krebsforschungszentrum, Heidelberg, Germany
J Natl Cancer Inst 92:690-8. 2000..Modifications in host-cell genes, most likely engaged in the control of HPV gene expression in proliferating cells, emerge as important events in HPV-mediated carcinogenesis...
- A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11Katharina Slupetzky
Laboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
Vaccine 25:2001-10. 2007..Induction of cross-neutralization Ab by L2 epitopes displayed on chimeric VLP represents a possible strategy for the generation of broad-spectrum vaccines to protect against relevant mucosal HPV and associated neoplasia...
- Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trialDiane M Harper
Department of Obstetrics and Gynecology, Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH, USA
Lancet 364:1757-65. 2004....
- Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiationWenyi Gu
Diamantina Institute for Cancer, Immunology and Metabolic Medicine, The University of Queensland, Research Extension, Building 1, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland 4102, Australia
Nucleic Acids Res 35:4820-32. 2007..It appears that aa-tRNAs in less-differentiated and differentiated KCs differentially match the PV Nat and Mod L1 mRNAs to regulate their translations in vitro...
- Transcription-modulatory activity of full-length E6 and E6*I proteins of human papillomavirus type 16H Shirasawa
Department of Microbiology, School of Medicine, Chiba University, Japan
Virology 203:36-42. 1994..The transcription-modulatory functions of full-length E6 and E6*I proteins suggested that transcriptional regulation of HPVs associated with mucosal malignant lesions is complex...
- AMF-1/Gps2 binds p300 and enhances its interaction with papillomavirus E2 proteinsY C Peng
Department of Dermatology, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA
J Virol 74:5872-9. 2000..These results suggest that AMF-1 facilitates the recruitment of p300 and its histone acetylase activity into complexes with E2 and represents a novel mechanism of transcriptional activation...
- Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potentialSara J S Simonson
McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, Wisconsin 53706, USA
Cancer Res 65:8266-73. 2005....
- E7-transduced human breast epithelial cells show partial differentiation in three-dimensional cultureK M Spancake
Huntsman Cancer Institute, University of Utah, Salt Lake City 84112, USA
Cancer Res 59:6042-5. 1999..These data suggest that loss of RB in vivo would compromise differentiation, predisposing these cells to future tumor-promoting actions...
- Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodiesBrooke Bishop
Department of Molecular and Computational Biology, University of Southern California, Los Angeles, California 90089, USA
J Biol Chem 282:31803-11. 2007..On the basis of these distinct surface loop structures, we have provided a molecular explanation for the type specificity of NmAbs against HPV infection...
- A splicing enhancer in the E4 coding region of human papillomavirus type 16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expressionMargaret Rush
Department of Medical Biochemistry and Microbiology, Uppsala University, Biomedical Centre, Husargatan 3, Box 582, 75123 Uppsala, Sweden
J Virol 79:12002-15. 2005....
- Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 proteinG Steger
Institut fur Virologie der Universitat zu Koln, Cologne, Germany
J Virol 71:50-8. 1997..Our results suggest a dose-dependent regulation of the HPV18 E6/E7 promoter by E2 due to variable occupancy of its binding sites, which have antagonizing effects on the activity of the E6/E7 promoter...
- Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancerTakuma Fujii
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo 160 8582, Japan
Int J Oncol 29:541-8. 2006..These results indicate that atelocollagen-mediated delivery of siRNA HPV18 E6 and E7 can be used as a novel therapeutic approach for cervical cancer...
- The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanismsKirsten Kabsch
Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany
J Virol 76:12162-72. 2002..We propose that inhibition of ligand-mediated apoptosis in human keratinocytes is a primary function of the HPV-16 E5 protein needed to prevent apoptosis at early stages of viral infection...
- RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatinLisa N Putral
Cancer Biology Program, CICR, R Wing, Princess Alexandra Hospital, Ipswich Rd, Brisbane, QLD 4102, Australia
Mol Pharmacol 68:1311-9. 2005..Our results provide strong evidence that loss of E6 and E7 results in increased sensitivity to cisplatin, probably because of increased p53 levels...
- Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleusMartin Sapp
Department of Microbiology and Immunology, Feist Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA 71130 3932, USA
FEBS J 276:7206-16. 2009..This minireview summarizes recent advances in our understanding of cell surface events, internalization and the subsequent intracellular trafficking of papillomaviruses...
- Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31Choongho Lee
Department of Microbiology Immunology, Feinberg School of Medicine, Northwestern University, Mail Code S213, 320 E Superior Street, Chicago, IL 60611 3010, USA
J Virol 78:12366-77. 2004..These results suggest that binding of E6 to PDZ proteins modulates the early viral functions such as proliferation and maintenance of the viral copy number in undifferentiated cells...
- Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccinationTae Heung Kang
Laboratory of Infection and Immunology, Graduate School of Medicine, Korea University, Gyeonggi Do, South Korea
Cancer Res 67:802-11. 2007..These results suggest that multimodality treatment strategies, such as combining immunotherapy with a tumor-killing cancer drug, may be a more effective anticancer strategy than single-modality treatments...
- Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18Deborah Stewart
Institute of Parasitology, Macdonald Campus, McGill University, Montreal, Canada, H9X 3V9
J Gen Virol 85:1419-26. 2004..These results provide insight into the cellular modulation of E6 protein levels from both high-risk and low-risk HPV types...
- Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoproteinYi Zhang
Molecular and Computational Biology, University of Southern California, 1050 Childs Way, MCB201, Los Angeles, CA 90089, USA
J Virol 81:3618-26. 2007..In addition to its novel insights into the biochemistry of PDZ interactions, this study is important for understanding HPV-induced oncogenesis; this could provide a basis for developing antiviral and anticancer compounds...
- Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cellsJ Wang
Center for Molecular Biology of Oral Diseases, College of Dentistry (M/C 860, University of Illinois at Chicago, 60612, USA
Oncogene 20:4740-9. 2001..Taken together, this study suggests that targeted inhibition of Rb proteolysis will be required for restoring Rb function in HPV-containing cervical cancer cells...
- Identification of an hnRNP A1-dependent splicing silencer in the human papillomavirus type 16 L1 coding region that prevents premature expression of the late L1 geneXiaomin Zhao
Department of Medical Biochemistry and Microbiology, Biomedical Center, Uppsala University, Husargatan 3, Box 582, 751 23 Uppsala, Sweden
J Virol 78:10888-905. 2004....
- E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class IG Hossein Ashrafi
Institute of Comparative Medicine, Department of Pathological Sciences, Glasgow University, Glasgow G61 1QH, Scotland, UK
Int J Cancer 113:276-83. 2005..Selective downregulation of cell surface HLA class I molecules may allow the virus to establish infection by avoiding immune clearance of virus-infected cells by both CTLs and NK cells...
- Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypesI Zehbe
Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany
Int J Cancer 94:711-6. 2001..01). This observation may explain why L83V is a risk factor more in Sweden than in the other 2 countries...
- Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targetingHeather Griffin
Division of Virology, National Institute for Medical Research, London NW7 1AA, UK
J Mol Biol 355:360-78. 2006....
- Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infectionRebecca M Richards
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Proc Natl Acad Sci U S A 103:1522-7. 2006..However, to our knowledge, furin has not been previously implicated in the viral entry process. This step is potentially a target for PV inhibition...
- Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNAViviane Bechtold
Swiss Institute for Experimental Cancer Research ISREC, 1066 Epalinges, Switzerland
J Virol 77:2021-8. 2003..Our results, together with those of others, suggest that any effect of the E2 protein on the expression of the E6 and E7 genes during the normal viral life cycle is of secondary importance compared to the function of E2 in replication...
- Human papillomavirus type 16 is an important infectious factor in the high incidence of esophageal cancer in Anyang area of ChinaT Li
Laboratory of Genetics, Beijing Institute for Cancer Research, School of Oncology, Peking University, No. 1 Da Hong Luo Chang St, Beijing 100034, China
Carcinogenesis 22:929-34. 2001..These results suggest that HVP-16 plays a causative role in the high incidence of esophageal cancer in the Anyang region of CHINA:..
- Genes involved in cell adhesion, cell motility and mitogenic signaling are altered due to HPV 16 E5 protein expressionN Kivi
Department of Virology, Haartman Institute, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
Oncogene 27:2532-41. 2008..These alterations may together lead to inhibition of apoptosis and facilitate the establishment of persistent infection in the epithelium...
- Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cellsNi Sima
Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, Hubei 430030, PR China
Gynecol Oncol 106:299-304. 2007....
- Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cellsA Hengstermann
Institute of Biochemistry I, Medical Faculty, University of Cologne, Joseph-Stelzmann-Strasse 52, , Germany
Proc Natl Acad Sci U S A 98:1218-23. 2001....
- Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoproteinT Veldman
Departments of Pathology and Oncology, Georgetown University Medical School, Washington, D.C. 20007, USA
J Virol 75:4467-72. 2001....
- Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface regionKazunari Kondo
Center for Pathogen Genomics, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
Virology 358:266-72. 2007..The cross-neutralization appears to be correlated with conserved aa sequences among HPV types. The data in this study provide a basis for designing vaccine antigens effective against a broader spectrum of the high-risk HPVs...
- Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilitiesEva Kehmeier
Department of Pharmacology and Toxicology, Philipps University Marburg, Karl von Frisch Strasse 1, D 35033, Germany
Virology 299:72-87. 2002..Analysis of functionally deficient HPV 16 E6 proteins in p53 null- and p53 wild-type-expressing cell lines revealed that the cellular steady-state level of this protein is influenced neither by its p53- nor its E6AP-binding abilities...
- Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcriptsN Hafner
Frauenklinik der Friedrich Schiller Universität, Jena, Germany
Oncogene 27:1610-7. 2008..Instead, constitutive expression of oncogene transcripts rather than the level of expression appears to be decisive for transformation and the maintenance of the malignant phenotype...
- Crystal structure of the E2 DNA-binding domain from human papillomavirus type 16: implications for its DNA binding-site selection mechanismR S Hegde
Department of Biochemistry and Program in Structural Biology, New York University Medical Center, Skirball Institute of Biomolecular Medicine, 540 First Avenue, New York, NY, 10016, USA
J Mol Biol 284:1479-89. 1998....
- Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2Ratish Gambhira
Department of Pathology, Johns Hopkins School of Medicine, 1550 Orleans Street, Baltimore, MD 21231, USA
J Virol 81:11585-92. 2007..Further, vaccination with HPV16 L2 11-200 generates broadly cross-neutralizing serum antibody, suggesting the potential of L2 as a second-generation preventive HPV vaccine antigen...
- CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour modelTai Gyu Kim
Department of Microbiology, The Catholic University of Korea, Seoul, Korea
Immunology 112:117-25. 2004..Thus, these data suggest that upon ODN stimulation DC might function as a potent adjuvant for E7 protein delivery for induction of protective cellular immunity against HPV E7-associated tumour challenge...
- Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancerChih Ming Ho
Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan, ROC
Gynecol Oncol 102:54-60. 2006..The aim of this prospective study was to analyze whether integration or high viral loads of human papillomavirus (HPV) is essential for malignant transformation of HPV types 52 and 58 as well as types 16 and 18...
- Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancerI Nindl
Department of Gynaecology, Gynaecologic Molecular Biology, Friedrich Schiller University, Jena, Germany
Int J Cancer 82:203-7. 1999..No statistically significant differences in the prevalence of the E6 or E7 prototype sequences, any variants or multivariants in German women with < or = CIN 1, CIN 2/3 or ICC were found...
- HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradationPaola Massimi
International Centre for Genetic Engineering and Biotechnology, Padriciano 99, Trieste I 34012, Italy
Oncogene 23:8033-9. 2004..These results suggest that in the context of HPV-induced transformation Dlg, MAGI-1 and MUPP1 can function as tumour suppressors...
- Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervixSoraya Khouadri
Laboratoire de Virologie Moléculaire du Centre de Recherche, Hôpital Notre Dame du Centre Hospitalier de l Université de Montréal, Montreal Quebec, Canada
J Infect Dis 194:886-94. 2006..We investigated the association between polymorphisms of human papillomavirus (HPV)-33 and squamous intraepithelial lesions (SILs)...
- p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer developmentI Zehbe
Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany
Cancer Res 61:608-11. 2001..Moreover, the frequency of the arginine allele was similar in groups with different E6 genotypes. It is concluded that p53 arginine is a risk factor for cervical cancer but probably acts independently of E6 variants...
- Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNAK Yamato
Molecular Cellular Oncology and Microbiology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
Cancer Gene Ther 13:234-41. 2006....
- Mechanisms of human papillomavirus-induced oncogenesisKarl Munger
Department of Pathology, Harvard Medical School, 77 Ave Louis Pasteur, NRB 0958C, Boston, MA 02115 5727, USA
J Virol 78:11451-60. 2004
- Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16Arvind Varsani
Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa and Department of Pathology, The Milton S Hershey Medical Center, Hershey, Pennsylvania, USA
J Virol 77:8386-93. 2003..Moreover, it contributes to knowledge of the structure of HPV-16 L1 VLPs and their derivatives...
- Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccinesChristina Schellenbacher
Laboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University Vienna, Austria
J Virol 83:10085-95. 2009....
- HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cellsF A Suprynowicz
Department of Pathology, Georgetown University Medical School, Washington, DC 20057, USA
Oncogene 27:1071-8. 2008..Finally, the upregulation of caveolin-1 and ganglioside GM1 at the plasma membrane of E5-expressing cervical cells provides potential new therapeutic targets and diagnostic markers for high-risk HPV infections...
- Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in miceTao Bian
Biotech Center for Viral Disease Emergency, Yingxin Street 100, Xuanwu District, Beijing 100052, People s Republic of China
Mol Cancer Ther 7:1329-35. 2008..Chimeric capsomeres are capable of preventing and eliminating HPV16 infection. Therefore, our study has provided an economical vaccine candidate...
- Intranuclear localization of human papillomavirus 16 E7 during transformation and preferential binding of E7 to the Rb family member p130K Smith-McCune
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco CA 94115, USA
Proc Natl Acad Sci U S A 96:6999-7004. 1999..Induction of E7 function was not correlated with binding to p130 or pRb but rather with intranuclear localization and modest induction of binding to p107...
- The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surfaceBarbara Marchetti
Institute of Comparative Medicine, Glasgow University Veterinary School, Garscube Estate, Glasgow G61 1QH, UK
Oncogene 21:7808-16. 2002..Lack of surface MHC I would have profound consequences for presentation of viral peptides to the immune system...
- The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptorsP Martin
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland 20892
Cell 59:21-32. 1989..We conclude that E5 may enhance the receptor activity via inhibition of receptor down-modulation...
- Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its typeS Nakagawa
Department of Obstetrics and Gynecology, University of Tokyo, Faculty of Medicine, Bunkyo ku, Tokyo, Japan
J Med Virol 62:251-8. 2000..Thus, the present study demonstrates that E6 and E7 transcripts of HPV exist in virtually all HPV-positive cervical neoplasia specimens except for the absence of E7 transcripts in some of CINs...
- A promoter within the E6 ORF of human papillomavirus type 16 contributes to the expression of the E7 oncoprotein from a monocistronic mRNAJacob A Glahder
The DNA Tumour Virus Group, Institute of Molecular Pathology, The Protein Laboratory, University of Copenhagen, Panum Institute, Bldg 6 2, Blegdamsvej 3C, DK 2200 Copenhagen N, Denmark
J Gen Virol 84:3429-41. 2003..In conclusion, we have found that P542 is a relatively weak promoter compared with P97 and may be downregulated in differentiated epithelial cells...
- HPV episomal copy number closely correlates with cell size in keratinocyte monolayer culturesPeggy A Garner-Hamrick
Genomics ID, Pharmacia Corporation, Kalamazoo, Michigan 49007, USA
Virology 301:334-41. 2002..The results also indicate that simple monolayer cultures may be useful for studying the relationship between differentiation, HPV DNA replication, and cell-cycle events...
- The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosisMaria Filippova
Department of Biochemistry and Microbiology, Center for Molecular Biology and Gene Therapy, Loma Linda University School of Medicine, Loma Linda, California 92354, USA
J Biol Chem 279:25729-44. 2004..These results support a model in which E6-mediated degradation of FADD prevents transmission of apoptotic signals via the Fas pathway...
- Viral oncoproteins target the DNA methyltransferasesW A Burgers
Wellcome Trust CRUK Gurdon Institute, University of Cambridge, Cambridge, UK
Oncogene 26:1650-5. 2007..These observations open up the possibility that this association may be used to control cellular proliferation pathways and suggest a new mechanism by which small DNA tumour viruses can steer cells through the cell cycle...
- Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccinesD M Da Silva
Cancer Immunology Program, Cardinal Bernardin Cancer Center, Department of Microbiology and Immunology, Loyola University Chicago, 2160 South First Avenue, Maywood, Illinois 60153, USA
Virology 290:350-60. 2001..This limitation could potentially be overcome by boosting with cVLPs containing the same target antigen incorporated into other papillomavirus-type VLPs...
- Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical carcinomaFrancoise Thierry
Institute of Medical Biology, Singapore, Singapore
Virology 384:375-9. 2009..We will describe the role played by the viral E2 proteins in the transcriptional repression of the high risk HPV oncogenes and its implication in cervical cancer...
- Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteinesMichael J Conway
Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
Virology 393:295-303. 2009..These results suggest that Cys28 is necessary for late-stage stabilization of capsids, while Cys22 is necessary for proper display of L2 neutralizing epitopes...
Research Grants68
- Genomic instability induced by the HPV-16 E7 oncoproteinStefan Duensing; Fiscal Year: 2009....
- Dendritic Cell Immunotherapy for Cervical CancerAlessandro Santin; Fiscal Year: 2004..This study will determine whether E7 antigen-loaded autologous DC vaccination offers the potential of therapeutic benefit for patients with HPV16 or HPV18-associated cervical cancer. ..
- A Phase I/II Trial of a Therapeutic HPV VaccineCornelia Trimble; Fiscal Year: 2004....
- THERAPEUTIC VACCINES FOR HPV DISEASESCornelia Trimble; Fiscal Year: 2005..These facilities will be used to develop Dr. Trimble's ability to design and execute clinical trials evaluating preneoplastic HPV-associated lesions of the female lower genital tract. ..
- Transcripitonal and Genetic Profiles in HNSCCsElaine Smith; Fiscal Year: 2008..abstract_text> ..
- CYTOTOXIC T LYMPHOCYTE RESPONSE TO HPV 16Mayumi Nakagawa; Fiscal Year: 2002....
- Therapeutic DNA-MVA prime boost vaccination for HPV diseaseCornelia Trimble; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- International Collaborative HNC ResearchElaine Smith; Fiscal Year: 2007..This aim is to determine whether there is an easily administered, sensitive biomarker that can predict HPV-HR status in HNC tumors prior to therapy.. [unreadable] [unreadable] [unreadable]..
- GENETIC EPIDEMIOLOGY AND MECHANISMS IN ORAL CANCERElaine Smith; Fiscal Year: 2003..abstract_text> ..
- Papillomavirus E2 as a cervical/anal cancer drug targetJanet Brandsma; Fiscal Year: 2005..Vectors containing a conditional wild-type CRPV E2 transgene will be used to determine the effects of E2 overexpression. ..
- MOLECULAR AND ONCOLOGIC VIROLOGY TRAINING PROGRAMDaniel DiMaio; Fiscal Year: 2005..In these capacities, he is well positioned to foster interactions among other members of the faculty in the School of Medicine. ..
- Anthrax DNA vaccine for non-invasive immunization on skinZhengrong Cui; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- A tri-antigen nasal anthrax vaccine against toxins and vegetative bacilli Zhengrong Cui; Fiscal Year: 2008..The same vaccine or its modified version can also be used in agricultural industries to vaccinate cattle. [unreadable] [unreadable] [unreadable]..
- Activation of NF-kB by Human PapillomavirusesCRAIG WOODWORTH; Fiscal Year: 2006..Therefore, our results will provide basic information on how HPV might alter host response to infection. [unreadable] [unreadable]..
- VSV-based Therapeutic Papilloma VaccineJanet Brandsma; Fiscal Year: 2007..The data provided by this investigation are likely to aid in the development a highly effective HPV vaccine to protect women against cervical cancer. ..
- Role of HPV16 E7/E2F6 interaction in viral oncogenesisMargaret McLaughlin Drubin; Fiscal Year: 2006..These studies will further the understanding of how viral proteins interact with cellular factors to induce cancer. [unreadable] [unreadable] [unreadable] [unreadable]..
- ANALYSIS OF THE PDGF RECEPTOR JUXTAMEMBRANE DOMAINDaniel DiMaio; Fiscal Year: 2004..These experiments should provide new insights into the function and regulation of receptor tyrosine kinases and into human tumorigenesis, and they should elucidate the binding properties of a new family of WW domains. ..
- p53 loss in HMECs: a model of breast cancer preventionVictoria Seewaldt; Fiscal Year: 2007..abstract_text> ..
- Real-Time Imaging of Hypoxia based on VHL ActivityWilliam Kaelin; Fiscal Year: 2006..unreadable] [unreadable]..
- Stress proteins in autoimmune depigmentationISABELLE LE POOLE; Fiscal Year: 2005..The same model will be of use to test the efficacy of therapeutic modalities to be developed for vitiligo in the future. ..
- Steroid As Cytoprotectants against Oxidative ToxicityQin Chen; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- ECM-Mediated Apoptosis in p53 (-) HMECsVictoria L Seewaldt; Fiscal Year: 2010..Significance: Completions of these aims will provide insight into early events in ER(-) mammary carcinogenesis and provide novel targets for breast cancer chemoprevention. ..
- HIV AND EBV INTERACTION IN ORAL MUCOSAL EPITHELIUMSharof Tugizov; Fiscal Year: 2005..The results of these studies will provide new and detailed information on the mechanisms of HIV infection of the oral mucosal epithelium and the role of HIV-EBV infection in oral interepithelial LCs in HIV pathogenesis. ..
- Regulation of BRCA1 Function by Protein Phosphatase 1Lih Ching Hsu; Fiscal Year: 2009..Lastly, we will also identify regulators of PP1 alpha activity toward BRCA1. ..
- Role of IGFBP -3 in mediating p53-induced apoptosisAdda Grimberg; Fiscal Year: 2006..These studies also reflect Dr. Grimberg?s long-term career goals of exploring the interrelatedness of endocrine and oncologic molecular biology principles and applying them to clinical problems of dysregulated growth. ..
- High Throughput Screen for SMAElliot Androphy; Fiscal Year: 2008..The objective is to define structure activity relationships (SAR) for lead optimization and subsequently test available structural analogues to identify pharmacologically active drug-like compounds. [unreadable] [unreadable] [unreadable]..
- The Role of Phosphatase CL100/MKP1 in Human CancerGen Wu; Fiscal Year: 2009..Collectively, our studies will provide important and novel insights into the role of CL100/MKP1 in cell cycle and apoptosis control in human cancer. ..
- COX-2 Inhibitors, APC and Colon Cancer PreventionKotha Subbaramaiah; Fiscal Year: 2009..These studies will enhance our understanding of the mechanistic link between COX-2 and colorectal cancer and potentially assist us in optimizing the use of selective COX-2 inhibitors as therapy. ..
- The XP Variant: A Human Mutator Gene for UV DamageJames Cleaver; Fiscal Year: 2005..We will express hRad3O on the keratin 14 promoter for over-expression in the skin, and make targeted knockout of mRad3O in vivo to identify roles for hRad3O in promoting and preventing carcinogenesis. ..
- A Luciferase Fusion Protein Library to Identify & Monitor Ubiquitylation TargetsWilliam Kaelin; Fiscal Year: 2008..Reisolation of HIF in aims 2 and 3 would constitute proof of concept with respect to the potential utility of this approach. ..
- EBV BMRF-2 Protein in Infection of Oral Epithelial CellsSharof Tugizov; Fiscal Year: 2007..These data will greatly advance knowledge of the mechanisms of EBV infection of oropharyngeal epithelial cells and may be of value to design new approaches to prevention of initial EBV infection. ..
- MOLECULAR EPIDEMIOLOGY OF LUNG CANCERChu Chen; Fiscal Year: 2010..g. Rosaceae fruits and Cruciferae vegetables), and food-derived nutrients (e.g. carotenoids, vitamin C, and vitamin E). ..
- ORAL CANCER: MOLECULAR PROFILES & CLINICAL OUTCOMESChu Chen; Fiscal Year: 2010..HPV plays an important etiologic role in some oropharyngeal cancers, we plan to determine and incorporate HPV genotypes in the analyses and interpretation of the study findings. ..
- Clinical & Cost Effectiveness of HPV Vaccination in the USSue Goldie; Fiscal Year: 2009....
- EVOLUTION OF IMMUNE RECOGNITION AND EVASIONAustin L Hughes; Fiscal Year: 2010..In addition, by increasing our understanding of the population diversity and evolutionary history of human immune system genes, this research will enhance our knowledge of human immune function in health and disease. ..
- An RNA Sensor for Detection of Circulating Tumor CellsGary Clawson; Fiscal Year: 2008..abstract_text> ..
- Molecular markers of breast cancer risk and preventionVictoria L Seewaldt; Fiscal Year: 2010....
- Integrin-Matrix Interaction in Cardiovascular DevelopmentLester F Lau; Fiscal Year: 2010..Together, these studies will provide novel insights into how CCN proteins regulate cardiovascular development through extracellular matrix signaling, and shed light on their roles in cardiovascular diseases. ..
- Study of genomic instability caused by HPV16 E6 and E7Dennis McCance; Fiscal Year: 2008..abstract_text> ..
- Functional Role of ATM-Ab1-RNAP II Signaling PathwayBaskaran Rajasekaran; Fiscal Year: 2008..abstract_text> ..
- FUNCTIONAL ANALYSIS OF THE E6AP UBIQUITIN PROTEIN LIGASEPeter Howley; Fiscal Year: 2007..unreadable]..
- EFFECT OF HPV-16 E7 ON DIFFERENTIATING EPITHELIAL CELLSDennis McCance; Fiscal Year: 2005..Additionally, we will investigate the ability of E7 to increase cyclin/kinase activity in differentiating cells, which also contain high levels of kinase inhibitors. ..
- Gene Duplication and Genome EvolutionAustin Hughes; Fiscal Year: 2004..5) Examining the role of transposable elements in duplication of genomic segments by testing for nonrandom association between these elements and putatively duplicated blocks in the yeast genome. ..
- MOLECULAR MECHANISMS OF OXIDANT TOXICITYQin Chen; Fiscal Year: 2004..We have a unique finding of premature senescence with oxidative stress and will combine in vitro and in vivo approaches to uncover the trigger of unwanted effects of aging. ..
- SPONTANEOUS REGRESSION BIOMARKERS IN CERVIX DYSPLASIAGloria Ho; Fiscal Year: 2003..DNA typing of class II HLA alleles by PCR will be performed using blood collected at baseline. Associations between these factors and regression of CIN will be assessed by appropriate univariate and multivariate analyses. ..
- INDUCIBLE GENES IN ANGIOGENESIS AND TUMOR GROWTHLESTER LAU; Fiscal Year: 2003..Third, the role of Cyr61 in tumor growth and metastasis will be evaluated, and intervention of Cyr61 activities will be explored as a means of restricting tumor growth. ..
- Mechanism of p12I and p30II in HTLV1 InfectionMichael Lairmore; Fiscal Year: 2003..Our long-term goal is to understand the role of p12-I and p30-II in the establishment of HTLV-1 infection in vivo. ..
- FUNCTIONS OF THE HUMAN PAPILLOMAVIRUS E6 ONCOPROTEINElliot Androphy; Fiscal Year: 2001..Studies to test the ability of this E6BP peptide to inhibit E6 interactions with E6BP and p53 in vivo will be performed. ..
- CYR61-Mediated Angiogenesis in Rheumatoid ArthritisLESTER LAU; Fiscal Year: 2002..Then we will explore Cyr61 as a potential therapeutic target. We will test whether blockade of Cyr6l function, using monoclonal antibodies or inhibitory peptides, can prevent or ameliorate arthritis and joint destruction. ..
- GENETIC EVENTS IN HUMAN PROSTATE CELL TRANSFORMATIONDavid Jarrard; Fiscal Year: 2002..In addition to addressing this critical mechanistic role in human prostate neoplasia, it will provide the applicant with a structured training program in molecular genetics in the laboratory of Dr. Catherine Reznikoff. ..
- Is Tissue ACE Required for Diabetic Renal Damage?Harold Franch; Fiscal Year: 2005..We believe that this approach will not only critically test our hypothesis, but will also lay the ground work for future studies into the role of ACE in the diabetic kidney. ..
- Using Synthetic Lethality to Select Cancer Drug TargetsWilliam Kaelin; Fiscal Year: 2005..Moreover, they may establish a new paradigm for the selection of anticancer drug targets based on inactivating mutations of TSG. ..
- Therapeutic Vaccine for EBV-associated Hodgkins DiseaseRajiv Khanna; Fiscal Year: 2005..The long-term aim of this project is to develop a rational basis for the delivery of a curative EBV-specific CTL immunity to not only in HIV patients with HD patients but also for non-HIV HD. ..
- Polymorphisms of INS/IGF Signal Pathways & Female CancerGloria Ho; Fiscal Year: 2006..This genetic study, in conjunction with the ongoing serological study, will provide a comprehensive examination of the role of the insulin/IGF system in tumorigenes ..
- Aspirin, Inflammation Markers, and Colorectal AdenomaGloria Ho; Fiscal Year: 2006..It may also identify target populations (e.g., those with high levels of proinflammatory cytokines) who may benefit most from chemoprevention of aspirin. ..
- Genetic Analysis of Papillomavirus Virion MorphogenesisCraig Meyers; Fiscal Year: 2009....
- Identification of downstream signals for Pitx2aQize Wei; Fiscal Year: 2006....
- HIV li-Key/Peptide VaccineMinzhen Xu; Fiscal Year: 2002..This entirely synthetic vaccine can be manufactured in a large scale and be given to those at high risk of HIV infection. ..
- Development of furanones for treatment of anthraxMartin Blaser; Fiscal Year: 2005..In initial studies, spores will be given subcutaneosly. Efficacy parameters will be defined as above. Successful trials can lead to phase I studies in humans, and treatment studies in non-human primates. ..
- li Suppression-enhanced HIV DNA VaccineMinzhen Xu; Fiscal Year: 2003..In a Phase II program Ii-RGC/gp120 DNA vaccines will be tested in non-human primates for the induction of a protective immune response against pathogenic HIV infection. ..
- CELL-SURFACE PROTEINS IN CAMPYLOBACTER FETUS VIRULENCEMartin Blaser; Fiscal Year: 2004..Finally, the data generated can be used to develop a mathematical model of antigenic variation that focuses on the relationship between microbial recombination generating diversity and host selection determining the direction of change. ..
- H PYLORI RECOMBINATION AND GASTRIC COLONIZATIONMartin Blaser; Fiscal Year: 2001..pylori infections. ..
- High Throughput Screen for Compounds to Treat Papillomavirus Induced CancersElliot Androphy; Fiscal Year: 2007..Success would impact the health of millions of women and men afflicted with HPV infections and associated malignancies. [unreadable] [unreadable] [unreadable]..
- PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENTT C Wu; Fiscal Year: 2003..A.5 Evaluate the mechanisms of the anti-tumor immunity induced by vaccination. ..
- ENHANCEMENT OF HPV16 E6 & E7-SPECIFIC ANTITUMOR IMMUNITYT C Wu; Fiscal Year: 2001..5) Perform head-to-head comparison of various E6, E7 and chimeric E6E7 vaccines in antitumor immunity using E6 and E7 expressing murine model tumors. ..
- Selection of chemical inhibitors of oncoproteinsMaurizio Bocchetta; Fiscal Year: 2002..Furthermore, the experiments proposed may contribute novel technology for the over-expression and purification of potentially any protein in actively replicating human mesothelial cells. ..
- MOLECULAR PATHOGENESIS OF SPINAL MUSCULAR ATROPHYElliot Androphy; Fiscal Year: 2004..Furthermore, SMN point mutants from SMA patients show defective oligomerization proportional to their disease severity. These studies have defined the genetic and biochemical basis for development of SMA. ..
- Papillomavirus Inhibitors for AIDS-related MalignanciesElliot Androphy; Fiscal Year: 2005..The optimal cellular delivery system for the best inhibitors will be defined. The overall goal is to achieve high potency in cell-based models for eventual testing in animals and in human clinical trials. ..


text: Artifact Details Title Encore Infinity 90 Catalog Number 102623931 Type Still image Identifying Numbers Other number P4138 Dimensions overall: 8 in x 10 in Description Color image of the Encore Infinity 90 Series. Image has 2 cabinets. The cabinets have doors with ventilation holes in bottom. Category Photograph Lot Number X7413.2015

subset: commoncrawl


text:
I'm 5'10-150lbs-34B now-31"rib cage-36-29-38-size 6-Athletic build. I want a very natural look-full full C. Silicone/Unders/Infram My surgery is in a month & my out of town doc said a minimum 371cc for my frame & measurements to make a difference. That seems big! Help!!! Don't want regrets later. Was not impressed with Vectra images-front image looked weird. I like 371cc rice sizers I made. Should I order the silicone sizers off ebay?? Does silicone under the muscle & being tall tuck a lot away?
Not Sure What Size Implant? I'm 5'10 150lbs 34B 31. (photo)
Doctor Answers 12
Implant size
Thanks very much for your question. I like to use sizers from Mentor which we have patients try on in the office. I then have patients photographed in their own clothing and then let them view this privately on line. I find that this is realistic and works well at giving patients a good idea of what to really expect. Based on your height and weight I would say something in the 350-400cc range sounds correct. But I would have to examine you to know for certain.
Implant size
That implant size seems right for someone with your build if you want to be a full C. It is a conservative size. The problem with using rice sizes is that the implants seem smaller when inside you and especially when under the muscle than when you try on a sizer.
Learn more: http://edelsonplastic.com/breast/breast-augmentation/
Implant Sizers
Thank you for your pictures. Using sizers from one of the implant companies is fine but is just another tool help guide everyone's decision. In my office once a lady determines she likes a certain sizer then I increase the volume I may ultimately use to match her desired look. The sizers sit on top of the skin and are not influenced by the muscle and skin which tend to restrict the true implant size to some degree. Additionally, in my experience taller women tend to handle larger volume implants better (400-500).
Dr. ES
You might also like...
Rice sizers do help determine how it will look on you...
and I'm not sure how you created a 371 cc sizer but if you were accurate and liked the look, you should be good to go. It is very hard to be perfect here but realize you will be fuller and closer to what you consider ideal. The biggest complaint I get from my patients is "I wish I went a little larger". At 5'10", you could carry a larger size if you wanted to. Enjoy your journey!
Breast augmentation in tall female
I think that if you l ike the volume that you did the rice test with and there is an implant of the proper dimensions that fits your body in that range, it may be reasonable for you to go with that volume. An exam in person would be essential.
Breast Enhancement Surgery
Since you are tall you could accomodate more of an implant than you think, that being said small implants are nice and more of something does not always mean better. I like 270-330 for someone like you
Choosing Implant size
I much prefer to help my patients choose their size in person, with sizers. When you are in the office in person with me, I can explain to you the difference in how sizers look in a bra as opposed to when they are implanted. If you are not able to see me prior to your surgery day, I would have three different sizes of implants available the day of surgery-choose your size the day of surgery using the sizers, and then return the unused implants or have them put them back into inventory. This is an important decision, and you want to make sure that you and your surgeon are truly on the same page with what your goals and expectations. I sometimes utilize Skype and phone consultation with pictures to view in this situation
Learn more: http://www.danmillsmd.com/gallery/breast-augmentation-silicone
Not Sure What Size Implant? I'm 5'10 150lbs 34B 31.
Poorly posted photos! Out of town surgery could be a problem. The size seems to small to me. Best to obtain IN TOWN second opinions !!
Not Sure What Size Implant?
It is not possible for us to give you an implant size without a consultation and examination. You need to let your surgeon know what look you want. He is paid to find the size that makes it happen. Picking an implant to get a desired look when you don't do that everyday as a profession is asking for a bad result.
Implant size
1.Dimensional planning
2.Gel Implant Sizing system
Dimensional planning – The measurements of your chest wall are taken. Also, the breast dimensions including the height, width, and current dimensions of each breast form the basis of dimensional planning. Based on these measurements, the implant size is recommended. This will give you a unique breast implant that is suited for your body frame. However, there are some limitations of what size we can recommend. For instance, some implants may just be too big for a narrow chest wall. Your surgeon can review this with you during the consultation.
Gel Implant Sizing system – During the preliminary breast implant consultation, you will be provided with an option to "try on" a variety of implant shapes and sizes. You can also visualize the possible outcomes of your surgery which helps you to get that perfect size to give you the shape that you longed for. This way your preferences are known and you can then pick a range of implants that will "fit" just right to give a soft natural fuller look. If you have decided on saline implants, then based on the gel sizer you select, we can guide you to the saline implant that achieves a similar look.
Hope this helps.
Dr. Basu
Houston, TX
Learn more: http://www.basuplasticsurgery.com/houston-breast-surgery/breast-sizing-consultation/
These answers are for educational purposes and should not be relied upon as a substitute for medical advice you may receive from your physician. If you have a medical emergency, please call 911. These answers do not constitute or initiate a patient/doctor relationship.


text:
Manchester United are waiting to discover if any of their injured players will return for Tuesday's Champions League tie against Olympiakos as they hope for a triple-defensive boost.
• Okwonga: Rooney strike keeps dark forces at bay
Centre-backs Jonny Evans and Phil Jones and right-back Rafael da Silva all missed Saturday's 2-0 win against Crystal Palace. Evans and Jones sat out United's training session on Monday, although Rafael participated.
But manager David Moyes, who had no option but to select Chris Smalling at right-back and Rio Ferdinand and Nemanja Vidic in the centre of defence at Selhurst Park, believes they could all be back in contention.
"We've got a few injuries but I'm hoping we might get a few of them back for Tuesday," he told United's official website. "We'll get a chance to see how Jonny Evans, Phil Jones and Rafael are and if they can join us."
Evans and Jones have both been sidelined by calf problems while Rafael suffered from concussion sustained in the 0-0 draw against Arsenal.
Moyes, who will definitely be without winger Nani, is anticipating a difficult test in Athens.
"They are really good and have had a great record," he added. "They are undoubtedly the best team in Greece, no question about it. They also have a lot of Greek internationals who will go to the World Cup and it will be a really tough game."
Use a Facebook account to add a comment, subject to Facebook's Terms of Service and Privacy Policy. Your Facebook name, photo & other personal information you make public on Facebook will appear with your comment, and may be used on ESPN's media platforms. Learn more.


text:
In the end, it all went just as expected: the latest 'dramatic day' in Italian politics ended just as it had began, with Silvio Berlusconi's government still firmly power.
Italy's embattled prime minister survived the second no-confidence vote in less than one year. But if last October, after the defection of his then second-in-command, the speaker of Parliament Gianfranco Fini, he scraped through by just three votes – 314 to 311 – this time he can boast a much stronger lead against the opposition: 316 to 301.
As GlobalPost reported this week, this was largely expected: the no-confidence vote had been called by his own People of Freedom of party, after Parliament unexpectedly rejected a key budget law.
The defeat was a sign of growing discontent and division inside his own coalition but it didn't mean that Italians – at lose those seated on the plush seats of the Italian 'Camera' – were ready to ditch him for good.
All's good and rosy then? Well, no.
Up to the last second, it seemed like a Parliamentary stratagem devised by the opposition might work: basically, they chose not to show up when they were first called to vote, hoping thus to void the vote altogether because too few deputies were present.
If this had happened, Berlusconi would have been forced to consult with Italy's president – the highly-respected Giorgio Napolitano, charged with the task of preserving the Constitution, to discuss his fate. Mind you, he would not have been forced to resign, but his already weak position would have been dealt another, probably fatal, blow.
But Berlusconi, just like last October, managed to convince some opposition deputies to come out in his favor.
In this case, five 'radical' deputies, elected as independents in the opposition Democrat Party ranks, showed up in the Parliament hall at the last minute.
Sure, they voted against his government, but with their arrival there were just enough deputies present to make sure that the vote would have been valid.
This convinced many 'teethering' centrist MPs, who had so far lounged in the Parliament antechamber, weighing their chances, to close ranks and vote en masse in favour the prime minister. And thus the result was sealed.
But this doesn't mean that Berlusconi's government is now ready to tackle Italy's economic situation. Immediately after the vote, the prime minister convened a cabinet meeting: but instead of presenting a long-anticipated package to stimulate jobs and growth, he rewarded some of the 'doubting' deputies who had voted for him in the morning with cabinet posts. The growth package, he promised, will be ready by next week.
Inside the prime minister's majority, there is growing uneasiness against austerity measures imposed by the Economics minister, Giulio Tremonti. After he said flatly that any new spending must be covered by cuts in the government, many have asked openly for his resignation.
Despite today's victory, when the new economic package is finally presented next week, it will have a hard time to make it through Parliament.


text:
The Willits City Council deferred consideration of the new city management structure proposed by City Manager Paul Cayler at its December 12 meeting. The council is expected to take up the issue at its January 9 meeting.
Cayler has proposed creation of a new director's position to head what would become the largest department within the city. The new public works director would have 23.1 "full-time equivalent" employees reporting to him or her. That group would be comprised of a six-person street maintenance crew, including lead; a three-person engineering crew, including the city engineer; a 6.5-person sewer plant crew; a 4.5-person water plant crew; a city pool seasonal staff; and a 1.4-person administrative group.
Why this organization structure was chosen was unexplained. Prior to the recession, several potential organization charts had been discussed by the council, but these were set aside due to fiscal realities.
The council decided to defer filling the public works director position after the last director retired in 2009. In 2009, the water, sewer and newly formed engineering group did not report to the public works director.
Councilwoman Madge Strong said she felt she needed to be briefed on any organizational discussions that had occurred in prior closed sessions before she could adequately consider the proposed organizational structure.
Newly elected Mayor Holly Madrigal concurred, and was directing the city manager to add this topic to the next closed session when she was interrupted by City Attorney Jim Lance. Lance reminded the council that, under the Brown Act, discussions about a new city organization should be conducted in the public eye.
Some councilmembers indicated a desire to wait to make any decision about hiring a new public works, sewer plant, water plant and engineering director until after the mid-year budget review. Cayler assured them costs and revenues were unlikely to change significantly from the figures presented by Finance Director Joanne Cavalleri to the council on December 12.
Cayler kept insisting the city's existing ad hoc organizational structure was undesirable, and was being stressed by the impending retirement of Community Development Director Alan Falleri. Cayler was specific about how the new organizational structure would better serve his desire to step back from the day-to-day work of the city and allow him to concentrate on other goals. He was less forthcoming about why this particular organization structure would best serve the needs of the city.
No discussion or background was presented to justify or reinforce the proposed organization chart. The proposed organization has two large departments containing 18.9 and 24.1 full-time equivalents, along with three organizations containing between two, 2.24 or four FTE reporting to the city manager.
Comparison of Willits staffing with Fort Bragg
Comparing city staffing and structures within California is a difficult task. Each California city is constitutionally allowed to provide police, firefighting, ambulance, water, sewer, other utilities, trash removal, recreation, roads, street lights, mosquito abatement, planning, building inspection, library services and more.
The population of each California city determines which of these services they are willing to pay the city to provide.
When Proposition 13 passed in 1978, the percent of property taxes allocated to each city was frozen in most counties. Cities providing more services at that time were typically allocated a larger percent of property taxes generated by the city.
While most cities now rely mainly on sales taxes for general fund revenue, property taxes are still an important funding source.
Willits provides police, water, some recreation, street repairs and lighting, planning and building inspection. The city does not subsidize or provide fire or ambulance services.
It negotiates a trash removal contract with Solid Waste of Willits and receives a franchise fee, which is paid to the general fund. For years the city has provided a small subsidy to the Mendocino County Library at Willits to keep it open at least one evening per week.
The California State Controller maintains a database of financial information for all cities, counties and special districts, but that data only includes personnel paid directly by the city.
According to the state controller's 2011 data, Willits had 4,989 residents and a city payroll of $2.7 million. This meant city employee wages and benefits cost each resident $560 in 2011. The number of city employees was listed as 44 fulltime employees and another 34 part-time employees, including members of the city council and employees who worked only part of that year.
The highest paid (salary and benefits) Willits workers in 2011 were the city manager at $150,905; a police sergeant at $150,064; police chief at $142,361; city engineer at $131,661; and a police sergeant at $131,362.
Fort Bragg with its 7,308 residents had 52 fulltime employees (plus 17 part-time). The city payroll costs were $3.5 million. The highest paid (salary and benefits) Fort Bragg workers in 2011 were the city manager at $187,258; police sergeant at $135,208; police officer at $127,909; police sergeant at $125,577; and public works director at $123,271. No police chief was listed. This computes to $461 per resident. Fort Bragg provides police services but hires Ukiah to provide dispatching services. It has a planning department but hires Mendocino County to provide building inspection services. Like Willits, it has a fire protection district providing fire protection within the city limits.
Organizational structures
According to most management courses, flat organizations tend to have lower costs, elevate each employee's level of responsibility, and typically have better coordination and speed of decision-making.
Flat organizations also have the potential for confusion about who is in charge, power struggles and reduced clarity about individual job functions. Large organizations that have successfully implemented flat organizational structures were forced to create smaller more manageable units.
A more hierarchical structure has more clearly delineated responsibilities and authority, especially benefitting large organizations. This structure reflects management organization adopted following the military chain of command used in World War II. While this structure promotes loyalty within a department, it sometimes hinders communication across departmental lines.
Hierarchical structures are frequently required in large organizations, due to the logistics of focusing the efforts of large numbers of individuals. It also is more costly and comes with an increase in bureaucracy and red tape.


text:
PROlonGed ExpoSure Sertraline (PROGrESS)
This study has been completed.
VA Ann Arbor Healthcare System
U.S. Army Medical Research and Materiel Command
Information provided by (Responsible Party):
Sheila Rauch, Atlanta VA Medical Center
ClinicalTrials.gov Identifier:
First received: January 27, 2012
Last updated: June 16, 2017
Last verified: June 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The current research study aims to compare the effectiveness of two proven treatments for posttraumatic stress disorder (PTSD): Prolonged Exposure (PE), sertraline, and their combination. In addition, the investigators are examining predictors of response to these two treatments and how PTSD symptoms, thoughts, and biological factors may be changed by such treatments. Biological mechanisms of change are also examined including emotion processing and regulation in fMRI, HPA axis function, and genetics and genomics. In addition, the investigators will examine acceptability of each treatment and reasons for ending treatment.
|Posttraumatic Stress Disorder
|Drug: Sertraline Behavioral: Prolonged Exposure Therapy
|Phase 4
|Study Type:
|Study Design:
|Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
|Official Title:
|Randomized Trial of Sertraline, Prolonged Exposure, and Their Combination for Post-traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF).
Resource links provided by NLM:
MedlinePlus related topics: Post-Traumatic Stress Disorder
Drug Information available for: Sertraline hydrochloride SertralineU.S. FDA Resources
Further study details as provided by Sheila Rauch, Atlanta VA Medical Center:
Primary Outcome Measures:
- Posttraumatic stress disorder (PTSD) symptoms as measured by the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS) [ Time Frame: 24 weeks ]
Secondary Outcome Measures:
- Posttraumatic stress disorder (PTSD) related psychopathology, including depression, alcohol and substance abuse, and general anxiety [ Time Frame: 24 weeks ]
|Study Start Date:
|November 2011
|Study Completion Date:
|May 2017
|Primary Completion Date:
|December 2016 (Final data collection date for primary outcome measure)
|Assigned Interventions
Active Comparator: Sertraline + enhanced medication management (SERT)
24 weeks of sertraline + enhanced medication management
Drug: Sertraline
Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
Other Name: Zoloft
Active Comparator: Prolonged Exposure + sertraline (PE/SERT)
Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
Drug: Sertraline
Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
Other Name: ZoloftBehavioral: Prolonged Exposure Therapy
up to 13 sessions of prolonged exposure
Active Comparator: Prolonged Exposure + placebo (PE/PLB)
Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
Behavioral: Prolonged Exposure Therapy
up to 13 sessions of prolonged exposure
|Ages Eligible for Study:
|Child, Adult, Senior
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria:
- Patient is an Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) combat veteran with chronic posttraumatic stress disorder (PTSD) or significant PTSD symptoms (Clinician Administered Posttraumatic Stress Disorder Scale [CAPS] >= 50) of at least 3 months duration
Exclusion Criteria:
- Current, imminent risk of suicide (as indicated on C-SSRS)
- Active psychosis
- Alcohol or substance dependence in the past 8 weeks
- Unable to attend regular appointments
- Prior intolerance or failure of adequate trial of prolonged exposure (PE) or sertraline (SERT) (defined as at least 2 months of SERT at least 100mg/day)
- Medical illness likely to result in hospitalization or for which treatments are contraindicated (based on lab results, medical history and physical exam)
- Serious cognitive impairment (as evidenced by cognitive impairment felt likely to interfere with the ability to participate meaningfully in the study)
- Concurrent antidepressants or antipsychotics
- Pregnant females
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01524133
Please refer to this study by its ClinicalTrials.gov identifier: NCT01524133
|United States, California
|VA San Diego Healthcare System
|San Diego, California, United States, 92161
|United States, Georgia
|Ralph H. Johnson VA Medical Center/Savannah Primary Care Clinic
|Savannah, Georgia, United States, 31406
|United States, Massachusetts
|Massachusetts General Hospital
|Boston, Massachusetts, United States, 02114
|United States, Michigan
|Veterans Affairs Ann Arbor Healthcare System
|Ann Arbor, Michigan, United States, 48105
Sponsors and Collaborators
VA Ann Arbor Healthcare System
U.S. Army Medical Research and Materiel Command
|Principal Investigator:
|Sheila Rauch, PhD
|VA Ann Arbor Healthcare System
More Information
Keywords provided by Sheila Rauch, Atlanta VA Medical Center:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 19, 2017
|Responsible Party:
|Sheila Rauch, Clinical Director of Wounded Warrior Project and Associate Professor at Emory University, Principal Investigator, Atlanta VA Medical Center
|ClinicalTrials.gov Identifier:
|NCT01524133 History of Changes
|Other Study ID Numbers:
|Study First Received:
|January 27, 2012
|Last Updated:
|June 16, 2017
Keywords provided by Sheila Rauch, Atlanta VA Medical Center:
combat-related PTSD
Posttraumatic stress disorder
prolonged exposure therapy
VA hospital
mental illness
Additional relevant MeSH terms:
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Trauma and Stressor Related Disorders
Mental Disorders
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
ClinicalTrials.gov processed this record on September 19, 2017


text:
In many ways, 2011 was by far the best season in the ten-year history of the Houston Texans. They won the AFC South and made the playoffs for the first time in franchise history, then beat the Bengals at home in the playoffs before falling to the Ravens on the road.
Despite such success, Texans fans were left to wonder what might have been. When Albert Haynesworth fell on Matt Schaub's right foot in a Week 10 win over the Buccaneers, the Texans were 7-3 and well-positioned to earn at least a first-round bye and possibly home field advantage through the playoffs. Rookie T.J. Yates played reasonably after backup Matt Leinart went down with his own season-ending injury, but the Texans still went 3-3 and slipped to the third seed.
Schaub is entering into the last year of his contract in 2012, so what does the future hold for him and the Texans at the quarterback position?
The first answer is that the job is Schaub's in 2012. While Yates played reasonably well, his inexperience and limited knowledge of the playbook forced the Texans to play more conservatively, particularly on third down. It's difficult to see a Schaub-led Texans team losing to either the Panthers at home or the woeful Colts, and Yates simply wasn't up to the challenge of making plays against a good defense like the Ravens in the postseason.
While Schaub also lost to the Ravens in the regular season, he made plays in a way Yates or Leinart couldn't do. If healthy, he's the unquestioned starter for the Texans.
Whether Schaub can stay healthy is a better question. His foot injury shouldn't provide any lingering problems in 2012. But this was the third year in his five with the Texans that he missed at least five games. The Texans' unsurprising response has been to invest in backup quarterbacks, first in Sage Rosenfels, then Dan Orlovsky, and finally adding Leinart and drafting Yates in the fifth round. Head coach Gary Kubiak has said Leinart and Yates will compete for the backup job in 2012. Given the Texans' cap situations and need to re-sign other players like Chris Myers, Arian Foster, and possibly Mario Williams, Yates' play may make Leinart expendable.
Schaub's injury history means that if Yates does make Leinart expendable, there's a good chance Yates starts a couple games in 2012. The Texans are probably hoping it won't be in the postseason again, but his injury history makes it a strong possibility. Can the Texans make a long-term commitment to Schaub, given that injury history?
Schaub when healthy has been a very good quarterback for the Texans. At 31 when next season begins, he's not likely to radically change who he is. He has a couple flaws as a passer, notably not a great downfield arm and occasional over-sensitivity to perceived pressure up the middle, but has been a very prolific passer when he's in the lineup. He threw for over 4,000 yards both years he started all 16 games, and has had an efficiency rate between above average and well above average every year with the Texans. He's perhaps the best play-faker in the NFL and is well-suited for the Texans' bootleg-heavy passing game. It's not unreasonable to think he could play at his established level for three to five more seasons.
The question the Texans have to face, though, is should he be their quarterback for those seasons? 2012 is not a question, but the salary cap situation that may lead to Leinart's release likely precludes them giving him a lucrative long-term extension until next season. Like Drew Brees in 2011, Matt Schaub will likely play out his contract and face a potential franchise tag designation next offseason.
Depending on Schaub's actual health and level of performance in 2012, and Yates' continued development, the Texans may make a different decision than the one the Saints will make this offseason and let Schaub go. Then again, maybe not. That will be up to Matt Schaub and how well and how often he plays this coming season.
{loadposition content1}


text:
McDaniels: Cutler will not be traded by Broncos
Published: March 3rd, 2009 | Tags: Denver Broncos, Jay Cutler, Josh McDaniels
Since word broke Saturday that Jay Cutler's name had come up in trade discussions, rumors have run rampant.
There has been speculation that Cutler could be traded to the Vikings, the Browns, the Buccaneers, the Jets — basically any team with a need at quarterback. But new Broncos coach Josh McDaniels spoke out Tuesday afternoon and attempted to squash any and all existing speculation.
"Let me be as clear as I can about this," McDaniels said when reached at his office Tuesday afternoon. "We are not trading Jay Cutler — period."
Let those words ring around the NFL, the Internet, the blogosphere, sports-talk radio. No matter how much trade talk there is regarding Cutler, it is not originating from Denver and, to the disappointment of many, it is not happening. In fact, further proof that Denver fully intends to keep Cutler is evidenced in its action. McDaniels and Cutler are scheduled to meet next week.


text:
BUCK, Ross J.
Date of death: 7 Aug 1972 – Indianapolis, Marion County, Indiana
Edinburgh Tri-County Enterprise, August 23, 1972
Funeral services were conducted by the Rev. Chilton Bowles at the Vandivier-Parsley Funeral Home south chapel Sunday afternoon for Ross J. Buck of Edinburg who died Thursday afternoon at the Methodist hospital in Indianapolis after a two years illness.
During the service, special music was sung by Oscar Mutz of Columbus accompanied by Mrs. B. G. Breeding, organist.
Burial was at Rest Haven Cemetery with Lowell Barrett, Don Nay, James Breeding, Bruce Buck, James Rowland, and John Pruitt serving as pallbearers.
Mr. Buck came to Edinburg in 1941 as an engineer for the Charles Hurd and Son Engineering Company when Camp Atterbury was surveyed. A 1907 graduate of Purdue University, he was Columbus city engineer from 1956 to 1957. He had worked for several years in Michigan and was with the Federal Public Works administration from 1934 to 1939. He also supervised the construction of the Music Hall at Purdue.
Born Oct. 2, 1887, in Michigan, he was the son of Willis and Ellen Brown Buck. He married Marie Breeding in 1961 and she survives.
Mr. Buck was a member of the Edinburg Presbyterian Church, the Masonic Lodge, and Knights Templar.
Surviving with his wife are one son, Ross W. Buck of Atlanta, Ga., two daughters, Kathryn Prucher and Marjorie Rowland, both of California; one step-son, George Breeding of Acton; two step-daughters, Dorothy Allen of Puerto Ordaz, Venezuela, and Frances Etzel of Cincinnati, Ohio.
Submitted by Mark E. Wirey


text:
March 15, 2013
Law & Politics has named Laura E. Beverage, Jackson Kelly PLLC attorney and columnist for Aggregates Manager's Rock Law, as a 2013 Colorado Super Lawyer.
Beverage co-authored Aggregates Manager's March Rock Law installment.
Kristin R.B. White and Meredith A. Kapushion were also included on the 2013 Colorado Super Lawyer list. The three women practice in Jackson Kelly's Occupational Safety and Health Practice Group, which focuses on the defense of state and federal civil and criminal enforcement matters in the area of occupational safety and health.
Attorneys in the Occupational Safety and Health Practice Group often represent clients in general industry, construction, manufacturing, chemical, trucking and mining, and has been actively involved in national regulatory proceedings and landmark cases since the the Occupational Safety and Health Act and Federal Mine Safety and Health Act were passed.
Beverage, along with seven of the firm's attorneys, was also included on the list of 2013 Women Leaders in Law and featured in The American Lawyer magazine in January.
Jackson Kelly received firm-wide honors as well.
The National Law Journal recognized the firm for having the second highest percentage of equity partners who are women among the top 250 firms in the country, while Law360 included Jackson Kelly on its list of 10 10 firms in the country for large percentage of female partners and, in 2011.
Additionally, the Women in Law Empowerment Forum (WILEF) awarded Jackson Kelly with the "Gold Standard Certification," a which recognizes law firms that have integrated women in top leadership positions.


text:
Modi axes all GoMs, eGoMs for fast decisions
The move signals a new style of functioning in which decisions are likely to be swift, and Modi, unlike his predecessor, will assert more authority instead of delegating power to cabinet colleagues.india Updated: Jun 23, 2014 16:22 IST
Prime Minister Narendra Modi on Saturday dismantled a process popular with the UPA regime, and one that was believed to delay policy decisions. In the new government's first frontal attack against red tape, it scrapped all empowered groups of ministers (EGoMs) and groups of ministers (GoMs) formed to decide on key policy matters and resolve differences.
The GoMs and EGoMs were small groups of ministers tasked by the PM to decide on specific issues. Recommendations by GoMs had to be approved by cabinet while EGoMs were authorised to decide on their own. The UPA government, widely accused of policy paralysis, had formed more than 125 GoMs and EGoMs.
Now, ministries will directly decide on policy. "Ministries and departments will process, at their level, issues pending before the EGoMs and GoMs and take decisions," said a government release. If ministries face difficulty in deciding, the cabinet secretariat and prime minister's office will step in.The move signals a new style of functioning in which decisions are likely to be swift, and Modi, unlike his predecessor Manmohan Singh, will assert more authority instead of delegating power to other cabinet colleagues.
The UPA regime referred almost all crucial policy matters — including Telangana, land acquisition and food security bills, modernisation of airports, spectrum allocation, bailout of Air India — to GoMs. This often led to tedious discussions and stressful delays. Telangana, for instance, was first referred to a ministerial panel in 2004. Discussions continued till 2012.
Defending the ministerial groups, former information and broadcasting minister Manish Tewari said, "The GoMs brought into play collective wisdom and institutional experience. It acted as a single window clearance system."
Congress spokesperson Rashid Alvi added, "Modi's government is just five days old. He has set an agenda for 100 days that does not mention price rise and welfare of minorities. It also has no deadline for bringing back black money. We will have to wait to see how he actually performs."
The move to abolish GoMs is in sync with Modi's emphasis on faster governance. After setting the agenda for 100 days, he has called the first meeting of the full council of ministers on Monday. Priorities will be spelt out and junior ministers are expected to get clear directions.
In Modi's shrunk cabinet, junior ministers are likely to be utilised a lot more and important work delegated to them.


text:
Scientific Publications by FDA Staff
Search Publications
Parasitol Int 2010 Jun;59(2):262-4
Comparative in vivo expression of amastigote up regulated Leishmania genes in three different forms of Leishmaniasis.
Sharma P, Gurumurthy S, Duncan R, Nakhasi HL, Salotra P
In Old World Leishmania infections in India, Leishmania donovani is responsible for visceral leishmaniasis (VL) and post kala-azar dermal leishmaniasis (PKDL) while L. tropica is responsible for cutaneous leishmaniasis (CL) in humans. The molecular differences between the two species of Leishmania and within the same species causing distinct pathologies that govern the outcome of infection and pathogenesis in the human host are unknown. Quantitative expression of selected genes was evaluated directly in lesion tissues of VL, PKDL and CL patients. Assessment of in vivo mRNA level highlighted substantial differences in gene expression patterns, providing an indication of the genes involved in pathogenesis in the three different forms of Leishmaniasis.
|Category: Journal Article
|PubMed ID: #19963076
|DOI: 10.1016/j.parint.2009.11.003
|Includes FDA Authors from Scientific Area(s): Biologics
|Entry Created: 2011-10-04
|Entry Last Modified: 2012-08-29


text:
my now 18 year old daughter got a job when she was 17. I was very impressed on how responsible she was. First this one family member told other family members that my daughter was not working. Then when they realized my daughter was working they had the attitude it would not last. It's like they are wanting her to mess up. A few days ago she quit her job, she told me and I was okay with it. She wants to get her high school diploma. She told her cousin that her friend got fiered for stealing and she got tierd of the boss bitching to her of it. (I can see this happening) Well, my daughters aunt told my husband that my daughter got fired for stealing. I asked my daughter and she told me about her friend. Then two days later the aunt calls to let my husband (her dad) know that she did not get fired that she quit her job. She just did not get the whole story. Why not get the whole story first?? I just felt hurt! needed to vent
Asked by Anonymous at 11:59 PM on Aug. 24, 2008 in Adult Children (18+)
Answer by girlneffy at 12:31 AM on Aug. 25, 2008
Answer by pupmom at 12:46 AM on Aug. 25, 2008
Answer by QueenBee216 at 12:11 AM on Aug. 28, 2008
Answer by LaurenKaye29 at 10:10 PM on Aug. 28, 2008
Next question in Adult Children (18+)
my kids are older teenagers and young adults do I belong here
Next question overall
i am from maryland and im confused about the desertion and abandonment...
Recently Bumped in Parenting
Just want to invite you go a new group!


text:
NEW YORK (TheStreet) -- ICYMI: Over the weekend a story with 24 pictures of an unkempt South LA Wal-Mart (WMT) blew up bringing considerable attention to ...
Walmart Obviously Doesn't Care Much About Apple's Image
And that got me thinking about the way large corporations respond (or not) to events that impact them.
Earlier this year I was somewhat surprised to see Apple (AAPL) react, presumably, in direct response to my work by placing air quality sensors in its Santa Monica store to determine the cause of a smell that initially reeked of body odor, but later took on something closer to a chemical smell.
I was in the same Apple Store over the weekend. I'm happy to report it smells great. Or, more accurately, it doesn't smell like anything. I have repeatedly asked Apple for details on the situation, but have not received a reply.
Anyhow, I was told by a person with considerable knowledge of Apple's inner workings that there's no doubt "heads would roll in Cupertino" in response to my reporting on the smell that, for a time and at times, seemed to overtake one of the company's flagship locations. Apple Santa Monica has been known to generate a million dollars a day in sales.
I'd love to be a fly on the wall, a tap on the telephone or an NSA email spy to intercept communications between Apple and Walmart. Because I have to assume if "heads would roll" over BO, shouldn't they explode in relation to something seemingly more important?